Nektar Therapeutics | NKTR - Gross Profit On Sales


Nektar Therapeutics reported $10.86M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Baxter International USD 1.14B 251M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 44.1B 5B Jun/2026
Dr.Reddys Laboratories INR 41.78B 4.02B Jun/2026
Eisai JPY 183.24B 29.83B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Exelixis USD 608.03M 17.17M Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026